TAFICTA EMTRICITABINE TENOFOVIR ALAFENAMIDE TABLETS

Get a Price/Quote

MOQ : 1 Bottle

TAFICTA EMTRICITABINE TENOFOVIR ALAFENAMIDE TABLETS Specification

Origin of Medicine
Allopathic

Dosage Form
Tablet

Salt Composition
Emtricitabine 200 mg, Tenofovir Alafenamide 25 mg

Indication
Human Immunodeficiency Virus (HIV-1) treatment

Pacakaging (Quantity Per Box)
30 tablets

Drug Type
General Medicines

Ingredients
Emtricitabine 200 mg, Tenofovir Alafenamide 25 mg

Physical Form
Tablets

Function
Antiretroviral therapy

Recommended For
HIV-1 infection in adults and pediatric patients

Dosage
As directed by the physician

Dosage Guidelines
Take one tablet once daily, with or without food

Suitable For
Adults and adolescents aged 12 years and above

Quantity
30 tablets per bottle

Storage Instructions
Store below 30C in a dry place. Protect from light and moisture.

Brand Name
TAFICTA

Prescription Required
Yes

Colour
White to off-white

Route of Administration
Oral

Shelf Life
24 Months

MRP
As per pack

Marketed By
Mylan Pharmaceuticals Private Limited

Shape
Film-coated, capsule-shaped tablets

TAFICTA EMTRICITABINE TENOFOVIR ALAFENAMIDE TABLETS Trade Information

Minimum Order Quantity
1 Bottle

Packaging Details
PACK OF 30 TABLETS

About TAFICTA EMTRICITABINE TENOFOVIR ALAFENAMIDE TABLETS

PRODUCT DETAILS

Brand Name: TAFICITA
Content: Emtricitabine &Tenofovir Alafenamide
Strengths:200 mg / 25 mg
Form: Tablets
Packing: pack of 30 Tablets
Manufactured By: Mylan

Note :- TAFICITA Is A Prescription Drug And Should Be Used Under Proper Medical Guidance And Advice. Do Not Share The Medicine With Others, Since They May Be Suffering From A Problem That Is Not Effectively Treated By This Drug................

Effective HIV-1 Treatment

TAFICTA tablets are specifically formulated for the management of HIV-1 infection in adults and adolescents. The combination of Emtricitabine and Tenofovir Alafenamide delivers potent antiretroviral activity, helping patients achieve viral suppression and improve immune function when administered as part of a prescribed regimen.

Convenient Once-Daily Dosage

Administration of TAFICTA is simple and convenient, requiring only one oral tablet per day, with or without food. This ease of use supports better adherence to therapy, which is crucial for long-term HIV treatment success and minimizing resistance.

Quality and Safety Assurance

Manufactured by Mylan Pharmaceuticals Private Limited, TAFICTA meets stringent quality standards. Each tablet is securely packaged to maintain stability and efficacy through its 24month shelf life. For optimal benefit, follow storage and usage instructions provided by the healthcare professional.

FAQs of TAFICTA EMTRICITABINE TENOFOVIR ALAFENAMIDE TABLETS:

Q: How should I take TAFICTA Emtricitabine Tenofovir Alafenamide Tablets?

A: TAFICTA should be taken orally, one tablet once daily, with or without food, as directed by your physician. It is important to follow your doctors instructions closely for best results.

Q: What is the main benefit of using TAFICTA for HIV-1 infection?

A: TAFICTA is an effective antiretroviral therapy that helps suppress HIV-1 viral load, supports immune system health, and can improve quality of life for patients age 12 and above when taken consistently as prescribed.

Q: When should I start taking TAFICTA?

A: You should begin TAFICTA treatment after your healthcare provider prescribes it based on your HIV-1 diagnosis and suitability for this therapy. Always consult your physician for the appropriate time to initiate treatment.

Q: Where should TAFICTA tablets be stored for optimum efficacy?

A: Store TAFICTA tablets below 30C in a dry place, away from direct light and moisture, to maintain their effectiveness throughout the 24-month shelf life.

Q: What is the process for obtaining TAFICTA tablets?

A: TAFICTA is a prescription medicine. To obtain it, consult a qualified healthcare professional, receive a prescription, and purchase it from authorized pharmacies or distributors in India.

Q: Who is TAFICTA suitable for?

A: TAFICTA is recommended for adults and adolescents aged 12 years and older who are diagnosed with HIV-1 infection, as assessed and prescribed by a healthcare professional.